Email Us
Call Us
Chimeric antigen receptor T-cell therapy has multiple regulatory approvals in hematologic malignancy, and xenograft evaluation in immunodeficient mice bearing human tumors remains the standard preclinical platform for CAR-T products before clinical translation. Altogen Labs conducts these studies across disseminated and solid tumor models, with antitumor activity, persistence, and trafficking measured within a single protocol.
The platform question in CAR-T work is more consequential than in most areas, because the host determines which parts of the biology are visible at all. To discuss model selection for a specific construct, request a quote.
Model selection and what each host reveals
Conventional immunodeficient hosts bearing human tumors support the core efficacy question: whether the construct recognizes its antigen, expands, and clears tumor. This is the appropriate first platform and the one on which most published CAR-T preclinical data rests.
What those hosts exclude is substantial. Macrophage activation, dendritic cell cross-presentation, and regulatory T-cell mediated suppression are absent from the system, and the cytokine-driven systemic toxicities observed in patients are not reproduced in standard immunodeficient xenografts. A construct evaluated only in that setting has been tested for antigen-directed killing and for little else.
Humanized hosts, particularly cytokine-transgenic configurations supporting human myeloid development, capture more of this biology. Mechanistic work indicates that cytokine release in these systems is driven substantially by monocyte-derived mediators, which is why a host lacking a human myeloid compartment cannot model it. Where release biology is the question, host selection is the study design decision that matters most.
Efficacy endpoints
Disseminated hematologic models established by intravenous injection of reporter-tagged leukemia or lymphoma cells are followed by longitudinal imaging, giving a burden trajectory for each animal rather than an endpoint comparison. Solid tumor models are followed by volume or by imaging depending on site.
Dose-response across CAR-T cell number establishes the relationship between product dose and tumor control, which is frequently non-linear and which informs the dose rationale carried into clinical development.
Persistence and trafficking
Durability of response in CAR-T therapy correlates with persistence more reliably than with peak expansion, and a study measuring only tumor burden cannot distinguish a product that cleared tumor and disappeared from one that cleared tumor and remained. Circulating CAR-T cells are quantified by flow cytometry at intervals through the study, and tissue distribution at termination establishes where the product localized.
In solid tumor models, trafficking into the tumor is a separate question from persistence in circulation, and immunohistochemistry distinguishes cells that entered the tumor mass from those that accumulated at its margin.
Applied examples
Dose-response in disseminated leukemia. A reporter-tagged leukemia model is treated with CAR-T cells at escalating doses, with burden followed by imaging and circulating product quantified weekly, distinguishing transient clearance at low dose from durable control with sustained persistence at higher dose.
Construct comparison. Two constructs differing in costimulatory domain are evaluated in matched cohorts, with expansion kinetics, persistence, and tumor control compared directly rather than across separate studies.
Cytokine release characterization. A construct is administered in a humanized host supporting human myeloid cells, with cytokines sampled densely in the hours after administration to characterize the release profile in a system capable of producing it.
Interpretive limits and service boundary
Preclinical efficacy signals in CAR-T xenograft models have been reported to discriminate somewhat poorly between constructs that subsequently succeed and fail clinically, and species-level differences in cytokine signaling, antigen density, and tumor-immune crosstalk limit the translational reach of any single model. These limits are stated in study reports rather than left for the reader to supply, and study design is directed at the specific questions a model can answer rather than at a general claim of clinical prediction.
Altogen Labs evaluates cell therapy products supplied by the client. Manufacture of CAR-T or other cell therapy products is not offered. All procedures are conducted under active IACUC protocols, with humane endpoints appropriate to disseminated disease and to the possibility of treatment-related cytokine effects. GLP standards are applied where a study is formally designated as GLP.
Send construct, target antigen, and the question the study must answer, or request a quote.